New drug uses for baricitinib

A technology of tinib and drug, applied in the field of medicine, can solve the problem of no reports of endogenous cardiomyocyte proliferation with baricitinib

Active Publication Date: 2022-04-05
SYNOGENBIOPHARMACO LTD NANJING CHINA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no relevant report on the induction of endogenous cardiomyocyte proliferation by baricitinib

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New drug uses for baricitinib
  • New drug uses for baricitinib
  • New drug uses for baricitinib

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Embodiment 1, baricitinib (Baricitinib) promotes the in vitro test of rat cardiomyocyte proliferation

[0040] (1) Culture of Cardiomyocytes of SD Rats

[0041] Cardiomyocytes from SD rats born 3 days old were isolated and cultured in DMEM high glucose medium (Hyclone) + 5% horse serum (GIBCO) at 37 degrees in a 5% carbon dioxide incubator.

[0042] (2) Experimental grouping and processing

[0043] Isolate cardiomyocytes from SD rats, add 5% horse serum (GIBCO) + DMEM high-glucose medium (Hyclone), and add cytarabine (final concentration 20umol / L) to inhibit the growth of non-cardiomyocytes. Infect cTnT-mAG-hGeminin (1 / 110) virus (MOI value of virus infection=100) after 48 hours of adherence, after another 24 hours, replace with DMEM culture medium containing 0.5% FBS, add drugs in groups, and group as follows:

[0044] a. Experimental group: treated with baricitinib (final concentration in the medium is 4 μmol / L) for 24 hours.

[0045] b. Blank control group: add th...

Embodiment 2

[0050] Embodiment 2, Baricitinib (Baricitinib) promotes the in vitro test of neonatal rat cardiomyocytes entering the cell cycle

[0051] Isolate cardiomyocytes from rats born 3 days old, add Baricitinib (final concentration in the culture medium is 2 μmol / l), use DMEM+DMSO as the control (control), wash three times with PBS after 48 hours, 4 Fix with %PFA (paraformaldehyde) at room temperature for 15 minutes, wash with PBS three times, block with 1% BSA / PBS / 0.1% Triton at room temperature for 1 hour, add primary antibody after 1 hour: Anti-α-Actinin (1:300, sigma, mouse, A7811) , Phospho-Histone H3 (Ser10) antibody (1:300, CST, rabbit, 9701S), Anti-Ki67 (1:300, abcam, rabbit, ab15580) overnight at 4°C, washed with 1% BSA / PBS / 0.02% Tween 4 times, add secondary antibody: goat anti-rabbit IgG (H+L) highly cross-adsorbed secondary antibody (1:500, Invitrogen, A32731), goat anti-mouse IgG (H+L) highly cross-adsorbed secondary antibody ( 1:500, Lifetechnologies, A21424), placed at...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicinal use of baricitinib. The use is the application of baricitinib or a pharmaceutically acceptable salt or ester thereof in the preparation of a drug for promoting cardiomyocyte proliferation. The present invention proves through experiments that the baricitinib can promote the proliferation of rat cardiomyocytes. Therefore, baricitinib can be used in related fields such as preparing drugs for promoting cardiomyocyte proliferation and drugs for treating or preventing heart disease, providing a new drug and treatment idea for treating or preventing heart disease such as myocardial infarction.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a new drug application of baricitinib. Background technique [0002] At present, cardiovascular disease has become the number one killer threatening human health. There are 40 million heart failure patients worldwide, and it has become the main cause of human death. Studies have found that cardiomyocytes in mammals gradually lose their ability to proliferate after adulthood. Once myocardial infarction occurs, the loss of cardiomyocytes will be irreversible. There are about 2-4 billion cardiomyocytes in an adult, about 25% of cardiomyocytes will be lost within a few hours after myocardial infarction, and the remaining cardiomyocytes have very limited proliferation ability, which is not enough to restore the contractile function of the heart, and the patient will eventually suffer from heart failure die. To solve this problem, in addition to surgery, basic translational resear...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/519A61P9/00A61P9/10C12N5/077
CPCA61K31/519A61P9/00A61P9/10C12N5/0657C12N2501/727
Inventor 卜晔杜建勇郑丽霞吴青朱小君熊敬维
Owner SYNOGENBIOPHARMACO LTD NANJING CHINA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap